Overview

Comparison of Vitreous Levels of Acular LS 0.04%, Xibrom 0.09%, and Nevanac 0.1%

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To compare the penetration of three different NSAIDs.
Phase:
Phase 4
Details
Lead Sponsor:
Innovative Medical
Treatments:
Bromfenac
Ketorolac
Nepafenac